Modulating influence on HIV/AIDS by interacting RANTES gene variants

RANTES (regulated on activation normal T cell expressed and secreted), a ligand for the CC chemokine receptor 5, potently inhibits HIV-1 replication in vitro. We tested the influence of four RANTES single nucleotide polymorphism (SNP) variants and their haplotypes on HIV-1 infection and AIDS progression in five AIDS cohorts. Three SNPs in the RANTES gene region on chromosome 17 (403A in the promoter, In1.1C in the first intron, and 3′222C in the 3′ untranslated region) are associated with increased frequency of HIV-1 infection. The common In1.1C SNP allele is nested within an intronic regulatory sequence element that exhibits differential allele binding to nuclear proteins and a down-regulation of gene transcription. The In1.1C allele or haplotypes that include In1.1C display a strong dominant association with rapid progression to AIDS among HIV-1-infected individuals in African-American, European-American, and combined cohorts. The principal RANTES SNP genetic influence on AIDS progression derives from the down-regulating RANTES In1.1C allele, although linkage disequilibrium with adjoining RANTES SNPs including a weaker up-regulating RANTES promoter allele (−28G), can modify the observed epidemiological patterns. The In1.1C-bearing genotypes account for 37% of the attributable risk for rapid progression among African Americans and may also be an important influence on AIDS progression in Africa. The diminished transcription of RANTES afforded by the In1.1C regulatory allele is consistent with increased HIV-1 spread in vivo, leading to accelerated progression to AIDS.

[1]  A. Garzino-Demo,et al.  HIV Infection and Pathogenesis: What About Chemokines? , 1999, Journal of Clinical Immunology.

[2]  Steven Wolinsky,et al.  RANTES production from CD4+ lymphocytes correlates with host genotype and rates of human immunodeficiency virus type 1 disease progression. , 2001, The Journal of infectious diseases.

[3]  J J Goedert,et al.  Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. , 2001, The New England journal of medicine.

[4]  M. Hammer,et al.  Global survey of genetic variation in CCR5, RANTES, and MIP-1α: Impact on the epidemiology of the HIV-1 pandemic , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Goedert,et al.  Characterization of high-risk HIV-1 seronegative hemophiliacs. , 2001, Clinical immunology.

[6]  R. Detels,et al.  Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study , 2000, AIDS.

[7]  S. O’Brien,et al.  Polygenic and multifactorial disease gene association in man: Lessons from AIDS. , 2000, Annual review of genetics.

[8]  S. O’Brien,et al.  The effect of genetic variation in chemokines and their receptorson HIV transmission and progression to AIDS , 2000, Immunological reviews.

[9]  S. O’Brien,et al.  Influence of CCR5 promoter haplotypes on AIDS progression in African–Americans , 2000, AIDS.

[10]  U. Wahn,et al.  Atopic Dermatitis Is Associated with a Functional Mutation in the Promoter of the C-C Chemokine RANTES1 , 2000, The Journal of Immunology.

[11]  S. Pahwa,et al.  Chemokine pattern in relation to disease state in human immunodeficiency virus-infected children. , 1999, AIDS research and human retroviruses.

[12]  K Fukutake,et al.  Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  W. Farrar,et al.  JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response. , 1999, Journal of immunology.

[14]  J. Farber,et al.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.

[15]  J. Goedert,et al.  Genetic acceleration of AIDS progression by a promoter variant of CCR5. , 1998, Science.

[16]  C. Kleeberger,et al.  CCR5 promoter polymorphism and HIV-1 disease progression , 1998, The Lancet.

[17]  S. Frøland,et al.  Circulating levels of RANTES in human immunodeficiency virus type 1 infection: effect of potent antiretroviral therapy. , 1998, The Journal of infectious diseases.

[18]  S. O’Brien,et al.  C-C chemokines, pivotal in protection against HIV type 1 infection. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J J Goedert,et al.  Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC) , 1998, Science.

[20]  A. Trkola,et al.  Genetic Subtype-Independent Inhibition of Human Immunodeficiency Virus Type 1 Replication by CC and CXC Chemokines , 1998, Journal of Virology.

[21]  L. Chess,et al.  Endogenous Production of β-Chemokines by CD4+, but Not CD8+, T-Cell Clones Correlates with the Clinical State of Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals and May Be Responsible for Blocking Infection with NonSyncytium-Inducing HIV-1 In Vitro , 1998, Journal of Virology.

[22]  U. Sharma,et al.  Chemokine-independent in vitro resistance to human immunodeficiency virus (HIV-1) correlating with low viremia in long-term and recently infected HIV-1-positive persons. , 1997, The Journal of infectious diseases.

[23]  J J Goedert,et al.  Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. , 1997, Science.

[24]  T. Schwartz,et al.  Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. , 1997, Science.

[25]  U. Tirelli,et al.  Serum levels of RANTES and MIP-1 alpha in HIV-positive long-term survivors and progressor patients. , 1996, AIDS.

[26]  J J Goedert,et al.  Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene , 1996, Science.

[27]  L. A. Martín,et al.  NIRCA: a rapid robust method for screening for unknown point mutations. , 1996, BioTechniques.

[28]  Steven M. Wolinsky,et al.  Relative resistance to HIV–1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high–risk sexual exposures , 1996, Nature Medicine.

[29]  S. Arya,et al.  Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.

[30]  J. Long,et al.  An E-M algorithm and testing strategy for multiple-locus haplotypes. , 1995, American journal of human genetics.

[31]  Jeremy MG Taylor,et al.  Resistance to HIV‐1 Infection , 1994 .

[32]  S. Buchbinder,et al.  Long‐term HIV‐1 infection without immunologic progression , 1994, AIDS.

[33]  A. Krensky,et al.  Genomic organization and transcriptional regulation of the RANTES chemokine gene. , 1993, Journal of immunology.

[34]  S M McKinlay,et al.  Hemophilia growth and development study. Design, methods, and entry data. , 1993, The American journal of pediatric hematology/oncology.

[35]  J. Phair,et al.  Acquired immune deficiency syndrome occurring within 5 years of infection with human immunodeficiency virus type-1: the Multicenter AIDS Cohort Study. , 1992, Journal of acquired immune deficiency syndromes.

[36]  J. Goedert,et al.  A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. , 1989, The New England journal of medicine.

[37]  M. Khoury,et al.  The use of attributable fraction in the design and interpretation of epidemiologic studies. , 1989, Journal of clinical epidemiology.

[38]  T. Schall,et al.  A human T cell-specific molecule is a member of a new gene family. , 1988, Journal of immunology.

[39]  D. Vlahov,et al.  Perspectives on infection with HIV-1 among intravenous drug users. , 1988, Psychopharmacology bulletin.